Biosyntia closes 1.5 million EUR round to launch world’s first bio-based vitamin B7
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
The combined company will be able to better serve both our global and regional customers with local production
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Younger Indians have a 10 times higher rate of heart attack
The award was presented to her during a virtual ceremony on the occasion of 8th International Day of Yoga on 21st June 2022.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Subscribe To Our Newsletter & Stay Updated